825 related articles for article (PubMed ID: 30499418)
1. Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.
Metyas S; Tomassian C; Messiah R; Gettas T; Chen C; Quismorio A
Curr Rheumatol Rev; 2019; 15(3):234-237. PubMed ID: 30499418
[TBL] [Abstract][Full Text] [Related]
2. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.
Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Lespessailles E; Hall S; Hochfeld M; Hu C; Hough D; Stevens RM; Schett G
Ann Rheum Dis; 2014 Jun; 73(6):1020-6. PubMed ID: 24595547
[TBL] [Abstract][Full Text] [Related]
3. Apremilast: A Novel Drug for Treatment of Psoriasis and Psoriatic Arthritis.
Haber SL; Hamilton S; Bank M; Leong SY; Pierce E
Ann Pharmacother; 2016 Apr; 50(4):282-90. PubMed ID: 26783350
[TBL] [Abstract][Full Text] [Related]
4. Apremilast and its role in psoriatic arthritis.
Sandhu VK; Eder L; Yeung J
G Ital Dermatol Venereol; 2020 Aug; 155(4):386-399. PubMed ID: 33050680
[TBL] [Abstract][Full Text] [Related]
5. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
[TBL] [Abstract][Full Text] [Related]
6. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
Keating GM
Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
[TBL] [Abstract][Full Text] [Related]
7. Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study.
AbuHilal M; Walsh S; Shear N
J Cutan Med Surg; 2016 Jul; 20(4):313-6. PubMed ID: 26848145
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain.
Queiro Silva R; Armesto S; González Vela C; Naharro Fernández C; González-Gay MA
Dermatol Ther; 2020 Nov; 33(6):e13961. PubMed ID: 32618402
[TBL] [Abstract][Full Text] [Related]
9. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
Edwards CJ; Blanco FJ; Crowley J; Birbara CA; Jaworski J; Aelion J; Stevens RM; Vessey A; Zhan X; Bird P
Ann Rheum Dis; 2016 Jun; 75(6):1065-73. PubMed ID: 26792812
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue.
Takamura S; Sugai S; Taguchi R; Teraki Y
J Dermatol; 2020 Mar; 47(3):290-294. PubMed ID: 31867729
[TBL] [Abstract][Full Text] [Related]
11. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.
Cutolo M; Myerson GE; Fleischmann RM; Lioté F; Díaz-González F; Van den Bosch F; Marzo-Ortega H; Feist E; Shah K; Hu C; Stevens RM; Poder A
J Rheumatol; 2016 Sep; 43(9):1724-34. PubMed ID: 27422893
[TBL] [Abstract][Full Text] [Related]
12. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
Wu JJ; Pelletier C; Ung B; Tian M
J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis.
Feldman SR; Pelletier CL; Wilson KL; Mehta RK; Brouillette MA; Smith D; Bonafede MM
J Comp Eff Res; 2019 Jul; 8(9):699-709. PubMed ID: 31081676
[No Abstract] [Full Text] [Related]
14. Drug safety evaluation of apremilast for treating psoriatic arthritis.
Busa S; Kavanaugh A
Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
[TBL] [Abstract][Full Text] [Related]
15. Safety evaluation of apremilast for the treatment of psoriasis.
Dattola A; Del Duca E; Saraceno R; Gramiccia T; Bianchi L
Expert Opin Drug Saf; 2017 Mar; 16(3):381-385. PubMed ID: 28132578
[TBL] [Abstract][Full Text] [Related]
16. Apremilast (Otezla). No progress in plaque psoriasis or psoriatic arthritis.
Prescrire Int; 2016 Jun; 25(172):149-51. PubMed ID: 27486641
[TBL] [Abstract][Full Text] [Related]
17. Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis.
Danesh MJ; Beroukhim K; Nguyen C; Levin E; Koo J
Dermatol Online J; 2015 Jun; 21(6):. PubMed ID: 26158370
[TBL] [Abstract][Full Text] [Related]
18. Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany.
Gandjour A; Ostwald DA
Appl Health Econ Health Policy; 2020 Feb; 18(1):109-125. PubMed ID: 31701482
[TBL] [Abstract][Full Text] [Related]
19. An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naïve patients with psoriatic arthritis.
Betts KA; Griffith J; Friedman A; Zhou ZY; Signorovitch JE; Ganguli A
Curr Med Res Opin; 2016; 32(4):721-9. PubMed ID: 26743448
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
Kawalec P; Holko P; Moćko P; Pilc A
Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
